# Role of ERBT Plus Intravesical BCG in Intermediate-Risk or High-Risk NMBC

> **NCT07724886** · NA · NOT_YET_RECRUITING · sponsor: **Chinese University of Hong Kong** · enrollment: 732 (estimated)

## Conditions studied

- Bladder Cancer

## Interventions

- **PROCEDURE:** Conventional Transurethral Resection of Bladder Tumour
- **PROCEDURE:** Transurethral En Bloc Resection of Bladder Tumour

## Key facts

- **NCT ID:** NCT07724886
- **Lead sponsor:** Chinese University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2029-12-31
- **Final completion:** 2030-03-31
- **Target enrollment:** 732 (ESTIMATED)
- **Last updated:** 2026-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07724886

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07724886, "Role of ERBT Plus Intravesical BCG in Intermediate-Risk or High-Risk NMBC". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07724886. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*